Education
About Us
Working with TipRanks
Follow Us
Active Biotech AB (DE:BTPC)
FRANKFURT:BTPC
BTPC Stock Chart & Stats
€0.01
<€0.01(14.29%)
At close: 4:00 PM EST
€0.01
<€0.01(14.29%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.03
Previous CloseN/A
Volume20.00K
Average Volume (3M)7.13K
Market Cap
€9.83M
Enterprise Value-€12.19M
Total Cash (Recent Filing)€65.10M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-5.53
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,636,067,100
10 Day Avg. Volume2,383
30 Day Avg. Volume7,129
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.11
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetBalance sheet leverage is minimal, with debt moving to zero in 2025. For a pre-commercial biotech, structurally low debt reduces refinancing pressure and interest burdens, preserving flexibility to fund development milestones and negotiate partnerships without heavy covenant constraints.
Partnering / Out‑licensing Business ModelActive Biotech’s asset-light model focuses on out-licensing and partnerships that yield upfront payments, milestones and royalties. This durable model lowers commercial capex needs, lets the company monetise R&D through larger partners, and scales value without building a sales organization.
Improving Cash Burn & Asset BaseOperating losses and cash burn have narrowed since 2022–2023 while total assets increased to 70.2M in 2025. This structural improvement extends runway potential, supports ongoing R&D activity, and reduces immediate financing urgency if the trend persists through subsequent periods.
Bears Say
No Product RevenueThe company reported zero revenue from 2021–2025, leaving no internal product cash flow. Structurally, absence of commercial sales means cash generation depends on partner milestones and licensing events, creating revenue unpredictability until a partnered product reaches market.
Persistent Losses & Negative OCFNet losses remain sizable (≈-37.3M in 2025) with materially negative operating cash flow. This sustained burn profile creates an ongoing need for external financing, raising dilution or funding-risk over the medium term and constraining capacity to expand or de-risk additional programs.
No Commercial Infrastructure / Marketed ProductsThe company is R&D-focused and lacks commercial manufacturing or sales operations. Structurally this increases dependence on partners for late‑stage development, regulatory approval and commercialization, lengthening time to sustainable revenues and concentrating execution risk outside of the firm's direct control.
Active Biotech AB News
BTPC FAQ
What was Active Biotech AB’s price range in the past 12 months?
Active Biotech AB lowest stock price was <€0.01 and its highest was €0.03 in the past 12 months.
What is Active Biotech AB’s market cap?
Active Biotech AB’s market cap is €9.83M.
When is Active Biotech AB’s upcoming earnings report date?
Active Biotech AB’s upcoming earnings report date is May 07, 2026 which is in 48 days.
How were Active Biotech AB’s earnings last quarter?
Active Biotech AB released its earnings results on Feb 12, 2026. The company reported >-€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by >-€0.001.
Is Active Biotech AB overvalued?
According to Wall Street analysts Active Biotech AB’s price is currently Overvalued.
Does Active Biotech AB pay dividends?
Active Biotech AB does not currently pay dividends.
What is Active Biotech AB’s EPS estimate?
Active Biotech AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Active Biotech AB have?
Active Biotech AB has 2,636,067,100 shares outstanding.
What happened to Active Biotech AB’s price movement after its last earnings report?
Active Biotech AB reported an EPS of >-€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Active Biotech AB?
Currently, no hedge funds are holding shares in DE:BTPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Active Biotech AB
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
Technical Analysis
Medivir AB
―
Isofol Medical AB
―
Xintela AB
―
Elicera Therapeutics AB
―
IRLAB Therapeutics AB Class A
―